Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04929847
Other study ID # 2021/060
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 20, 2021
Est. completion date September 1, 2022

Study information

Verified date February 2023
Source Jessa Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Notwithstanding the continuous progress in cancer treatment, patients with cancer still have to cope with quality of life (QoL) - impairing complications. Especially an extensive spectrum of dermatologic toxicities has been associated with cancer treatments. The number and type of cutaneous toxicities have evolved over the past 50 years, paralleling the development of new chemotherapeutic agents. The chemotherapy-related skin toxicities can significantly impede the patient's emotional, physical, social, and financial well-being resulting in a poor QoL. In rare cases of severe cutaneous reactions, treatment modifications are needed, resulting in a diminished overall survival. Important organizations in the field of oncology and supportive care, such as the MASCC, the ASCO, and the ESMO, have developed guidelines for the management of cancer therapy- related cutaneous toxicities based on available scientific evidence. Still, for some interventions, the evidence of recommendation is moderate to insufficient. Therefore, it is essential to elucidate other new potential management strategies for dermatological complications of cancer treatment. Based on the previously mentioned supportive care guidelines for the ChemoSkin project, a novel emollient to tackle the cutaneous adverse events of chemotherapy has been developed. The ChemoSkin project general aim is to evaluate the efficacy of a novel skincare product to manage chemotherapy-related cutaneous toxicities.


Description:

Primary objective Evaluate the efficacy of a novel emollient for the management of chemotherapy-related cutaneous adverse events Secondary objective 1 Evaluate patient-relevant treatment benefit of the novel emollient for chemotherapy-associated cutaneous toxicities Secondary objective 2 Evaluate the influence of the novel emollient for chemotherapy- associated cutaneous toxicities on the patient's quality of life Secondary objective 3 Evaluate the safety of the novel emollient for chemotherapy- associated cutaneous toxicities


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 1, 2022
Est. primary completion date September 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with cancer of any type - Undergoing chemotherapy at the Jessa Hospital (Hasselt, BE) - Age = 18 years - Able to comply to the study protocol - Able to sign written informed consent Exclusion Criteria: - Pre-existing skin rash, ulceration, skin infections or open wounds - Severe psychological disorder or dementia - Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Self-prepared emollient
The emollient is hypo-allergenic, free of perfume and has very high hydrating capacities together with antioxidants.

Locations

Country Name City State
Belgium Jessa Ziekenhuis VZW Hasselt Limburg

Sponsors (2)

Lead Sponsor Collaborator
Jessa Hospital Hasselt University

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other General patient-, disease-, and treatment-related information General and medical information will be collected through a short patient questionnaire in order to assess intrinsic risk factors (i.e., gender, age, smoking history, work habits, physical activity, skin condition, alcohol use, and medication use). Furthermore, information about disease- and treatment-related risk factors will be collected through medical records (e.g., tumor type and stage, tumor site, treatment type, radiotherapy regimen). Baseline
Primary Skin reaction evaluation The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5. Baseline
Primary Skin reaction evaluation The severity of the skin reactions will be evaluated by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5. Week 3 of chemotherapy (End of study)
Primary Patient benefit composite The Patient Benefit Index is a standardized questionnaire measuring patients' treatment needs and treatment benefits for skin diseases. The PBI comprises two components:
Patient Needs Questionnaire measuring the importance of different treatment goals from the patient perspective.
Patient Benefit Questionnaire measuring the achievement of the treatment goals from the patient perspective.
Baseline
Primary Patient benefit composite The Patient Benefit Index is a standardized questionnaire measuring patients' treatment needs and treatment benefits for skin diseases. The PBI comprises two components:
Patient Needs Questionnaire measuring the importance of different treatment goals from the patient perspective.
Patient Benefit Questionnaire measuring the achievement of the treatment goals from the patient perspective.
Week 3 of chemotherapy (end of study)
Secondary Patient subjective evaluation of skin reactions The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale Baseline
Secondary Patient subjective evaluation of skin reactions The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale Week 1 of chemotherapy
Secondary Patient subjective evaluation of skin reactions The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale Week 2 of chemotherapy
Secondary Patient subjective evaluation of skin reactions The patients will be asked to complete a questionnaire to evaluate the intensity of five common symptoms of skin reactions: pruritus, dryness, erythema, burning sensation, and pain on an 11-point Numerical Rating Scale Week 3 of chemotherapy (end of study)
Secondary Quality of life - DLQI Dermatology Life Quality Index (DLQI) is a questionnaire with 10 items and is used to measure QoL of dermatological patients. Baseline
Secondary Quality of life - DLQI Dermatology Life Quality Index (DLQI) is a questionnaire with 10 items and is used to measure QoL of dermatological patients. Week 3 of chemotherapy (end of study)
Secondary Quality of life - Skindex-29 The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items). baseline
Secondary Quality of life - Skindex-29 The skindex-29 is a validated instrument to measures patients' QoL specifically correlated with skin conditions. It has 3 scales addressing emotions (10 items), symptoms (7 items) and functioning (12 items). Week 3 of chemotherapy (end of study)
Secondary Patients' satisfaction with the therapeutic intervention The patients will be asked to evaluate the general pleasantness and soothing effect of the skin care products by using a numerical rating scale. Week 3 of chemotherapy (end of study)
See also
  Status Clinical Trial Phase
Recruiting NCT04929834 - Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities N/A
Not yet recruiting NCT03606954 - Potency of Topical Corticosteroids in Combination Preparations Phase 4
Completed NCT01976481 - Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27 N/A
Completed NCT03448731 - Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA) Phase 2
Recruiting NCT05109858 - Skin Toxicity by Oncological Therapies
Completed NCT00871429 - Skin Care for Cancer Patients: A Product Satisfaction Survey N/A
Recruiting NCT04469075 - Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields Phase 2
Recruiting NCT04650256 - Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences N/A
Terminated NCT01317433 - Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer N/A
Active, not recruiting NCT03167268 - Panitumumab Skin Toxicity Prevention Trial Phase 2
Recruiting NCT06118047 - Crisaborole Ointment for Skin Toxicity Induced by Cetuximab Phase 2